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 Traumatic brain injury (TBI) is the leading cause of death and disability among 
young adults. Thus, discovering a biomarker to assess the severity of TBI is an issue of 
immense clinical importance. This systematic review aims to evaluate the potential for 
neuron specific enolase (NSE) to identify TBI in animal studies.   
Methods 
 MEDLINE and Pubmed were searched for relevant literature up to January of 
2017. Studies were included as part of the review if they included animal species, age, 
sex, injury severity, injury model, sampling site, number of animals per injury group, at 
least one outcome measure, and number of time points for recording the biomarker in 
question. Risk of bias was assessed by the Quality Assessment of Diagnostic Accuracy 
Studies tool (QUADAS-2). 
Results 
 3411 citations were screened, of which 20 were considered for final review. NSE 
was generally found to be a positive predictor for TBI. 
Conclusions 
 In preclinical trial data involving TBI, increased levels of NSE correlate with injury 
severity. Inconsistent data reporting standards and lack of consistency involving injury model 







Traumatic Brain Injury (TBI) is characterized by a traumatic insult to the brain 
that causes acute or chronic dysfunction. In animal models, TBI is characterized typically 
after a blow to the head or skull, and can be classified by both location (open or closed 
skull) and severity (mild, moderate, or severe).1 In addition to a clinical exam, a 
qualitative collection of symptoms from patients and imaging, TBI diagnosis focuses in 
part on the use of the Glasgow Coma Scale (GCS), a metric by which physicians 
determine the severity of a brain injury based on three criteria: ability to speak, ability to 
open eyes, and ability to move.2 A practitioner will rate a patient’s ability to function in 
these areas on a scale from 3 to 15; a higher number indicates an injury that is less severe. 
The primary issue with using the GCS as a diagnostic tool is that it is inherently 
subjective, severely limiting its utility. Unfortunately, this scale is a crude assessment of 
neurological function and therefore ignores many features important to TBI diagnosis. 
Other research being performed focuses on the use of novel neuroimaging technology, 
but these techniques are far from being clinically relevant.3 
Clearly, there is a great need to be able to accurately and consistently diagnose 
TBI; it has also been established that current diagnostic methods are limited and are not 
always representative of the patient’s true injury state. Biomarkers have emerged as a 
potential means of accurately diagnosing TBI. A biomarker can be defined as any 
biological sign that can be used to capture the pathophysiology accurately. In this review, 
blood biomarkers will be investigated.  
A well-suited biomarker is one which consistently can be used diagnostically to 
determine the severity of TBI in patients. Neuron-specific enolase (NSE) is dimeric 
isozyme primary located in the cytoplasm of neurons. NSE is only released from this 
cytoplasm in the case of neuronal damage to maintain homeostasis.4 It is believed that 
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this quality of NSE makes it an ideal biomarker for TBI severity.  A systematic review on 
the current research spectrum of biomarkers has the potential to determine which 





 A protocol was developed following the guidelines of the Cochrane 
Collaboration.5 Results were reported using the standards included in the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.6 
Search Strategy  
 Utilizing both MEDLINE and Pubmed as primary databases, a literature search 
was conducted to locate relevant studies published up to October of 2016. The specific 
search terms used is as follows: (TBI OR traumatic brain injury OR head injury) AND 
(rodent OR animal OR mouse OR rat) AND (biomarker OR S100B or NSE or GFAP or 
UCH-L1 or Tau). Unpublished data were not sought. Reference lists from included 
articles were not reviewed for further citations.  
Study Selection 
 Relevant studies were imported into Endnote X7, and duplicates were excluded 
from consideration. After this step, selection was done manually. Studies were included if 
an outcome measurement or an inclusion of TBI severity (mild, moderate, severe) was 
included, if a serum or CSF sample was taken within 24 hours of injury with the intention 
of checking relative biomarker levels, and if a biomarker in question was being 
measured. Accepted studies were limited to those written in the English language 
regarding rodents. Only studies that included a full-text PDF were included; studies 
limited to abstracts or review articles were excluded from this study.  
Data Abstraction 
 Data were extracted by a pair of reviewers and any disagreements were resolved 
through discussion. The following terms were recorded: study characteristics (year of 
publication, ISSN), subject characteristics (species of animal, age of animal, sex of 
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animal, number of animals per treatment group), injury characteristics (injury severity, 
injury model), biomarker-measuring characteristics (location of biomarker sampling, 
assay, number of time points, time of biomarker collection), and outcome evaluation. In 
the case of multiple studies from the same author, measures were taken to ensure that 
different test subjects were used.   
Assessment of Risk of Bias 
 To evaluate the extent of risk-of-bias, the Quality Assessment of Diagnostic 
Accuracy Studies tool (QUADAS-2), a set of procedures created to assess the quality of 
studies collected for systematic reviews, was utilized.7 Review Manager version 5.3 was 
utilized to create a Risk of Bias table.  
Statistical Analysis 
 A quantitative meta-analysis was considered. In the case that data was 
homogeneous enough to be considered for a statistical analysis, effect sizes from multiple 
studies would have been pooled to create a common effect size and determine 





 The proposed search strategy found 3411 citations, 20 of which were considered  
for final review with full texts (Figure 1). Endnote removed 823 duplicates automatically, 
and 2427 citations were removed through preliminary title and abstract screening using 
Endnote’s Smart Groups function. Smart Groups were organized as follows: Tau Protein  
 
Figure 1: Flow diagram for the selection of studies. 20 studies met the final requirements for this 
systematic review. 
 7 
(Cleaved Tau Protein, P Tau, Cleaved-tau, C-tau), GFAP (glial fibrillary acidic protein), 
S100B (S100B, S100 calcium-binding protein B, S100), UCH-L1 (UCH-L1, Ubiquitin 
carboxyl-terminal esterase-L1, UCHL1), and NSE (NSE, neuron-specific enolase). 
During study selection, further potential biomarkers were discovered and added to the 
search terms for Smart Groups. They are as follows: BMX (BMX), MBP (MPB, Myelin 
Basic Protein), Spectrin Breakdown Products (Spectrin Breakdown Products, Spectrin 
Breakdown Product, SBP, SBPs), and NF-H (NF-H, neurofilament subunit NF-H, 
neurofilament H). Ultimately, not enough full-text studies of these extra biomarkers that 
met inclusion criteria were found. As such, they were removed from consideration of this 
systematic review.  
 As full-text references were found, it became apparent that there was great 
variation in reporting of studies in terms of outcome measures, injury model, injury 
severity, and data reporting. The wide array of reporting standards among studies 
invalidated the feasibility of a quantitative meta-analysis. NSE was chosen to be 
examined as the sole biomarker in this review due to its close association with neural 
activity. Results were therefore summarized qualitatively.  
Study Characteristics  
 In total, 851 animals were used across 20 studies. The number of animals 
included in the studies ranged from 11 to 140. Out of the twenty studies included in the 
qualitative analysis, fourteen used rodents as subjects, three used swine, two used goats, 
and one used cats. Six studies reported their injury severity in terms of mild, moderate, or 
severe (n = 210).8,9,19,25,26,27 Seven studies reported outcome measures not tied to the 
severity of the injury given or the relative amount of biomarker present (n = 
471).10,11,14,17,18,21,27 The most frequent outcome measurement for behavior was the water 
maze, which was utilized by two studies (n = 102).17,27 Six studies measured NSE 
concentrations via CSF, while fifteen measured blood serum levels. Two measured both 
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CSF and serum levels for NSE.24,25 Eleven studies measured NSE levels with an enzyme-
linked immunosorbent assay (ELISA) test and three utilized reverse phase protein 
microarray (RPPM). Seven studies used a blast model of TBI (n = 351), three used a 
weight drop model of TBI (n = 88), three used controlled cortical impact (n = 169), and 
three used a fluid percussion model (n = 132). One study injured multiple organs in 
addition to TBI to measure relative NSE concentrations.21 The earliest delay between 
injury and measurement of NSE concentration was immediately in four studies (n =220), 
thirty minutes in two studies (n = 18), one hour in four studies (n = 228), six hours in five 
studies (n =211), and twenty-four hours in five studies (n = 253).  Most studies found that 
NSE levels peaked at six hours. Several studies measured NSE levels as a confirmation 
of TBI severity and not as the primary goal. Fifteen studies found that NSE levels 
increased significantly after TBI and four studies found that NSE did not increase 
significantly after TBI. One study concluded that TBI increased in CSF, but not serum. 
Additional properties of the included studies are reported in Table 1.  
Risk of Bias 
 Risk of bias was examined using a modified QUDAS-2 test. Subject selection had 
the least amount of bias, while flow and timing had the highest risk for bias. Figure 2 




Figure 2: Risk of bias and applicability concerns for studies included in systematic review. 
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Table 1 (part 1 of 2): Characteristics of Included Studies 
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 Twenty trials were found that recorded NSE levels after TBI. These trials, which 
induced TBI with various injury models, suggest that NSE has potential as a diagnostic 
biomarker for TBI. Most trials used different outcome measurements to assess TBI 
severity.   
 Although one inclusion criterion of this review was that samples were taken prior 
to 24 h post injury, many studies took NSE concentration levels both after 24 h and 
before 24 h. In these studies, NSE levels lowered significantly more in the 24-72 h 
timeframe compared to the 6-24 h timeframe. This suggests that, when determining 
future treatment options for TBI, diagnoses using NSE as a biomarker should take place 
prior to 24 h post injury. However, despite NSE’s promise, it has its limitations. In 
studies that damaged multiple organs, NSE levels were found to have a low specificity 
for determining outcomes in TBI. In addition, serum levels of NSE are known to increase 
in patients with certain types of lung cancer, renal failure, and pulmonary diseases.28 
Another issue is hemolysis, which increases the concentration of NSE due to its presence 
in erythrocytes. Utilizing NSE in this manner may lead physicians to believe that a brain 
injury is more severe due to damage in other parts of the body, leading to an 
overestimation of TBI severity in patients.  
 CSF levels of NSE are commonly thought to be a better estimation of central 
nervous system damage than serum levels, notably in acute conditions including both 
encephalitis and neurocyticerosis.4 In studies that measured both CSF and serum levels, 
CSF was a better indicator of neuronal outcomes.4 
 This systematic review suffered from many limitations. First, the lack of studies 
that fit the set inclusion criteria. Second, there was a large amount of heterogeneity 
among outcomes in the included studies. Third, the time between sample collections 
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varied greatly from study to study. Even though every study had at least one 
measurement that was taken at or before the twenty-four-hour mark post-injury, some 
took samples as soon as immediately after injury and never again, and others continued to 
take samples a week after injury. Fourth, even though risk of bias was carefully assessed, 
risk is inherent in the quality of the selected studies. The results of the QUADAS-2 
assessment demonstrate that publication bias cannot be ignored. Fifth, although the 
sampling location of NSE did not appear to significantly affect results, there were not 
enough CSF studies to assess their relative efficacy. Finally, the severity and model of 
TBI varied from study to study. Blast injuries, for instance, can result in extracranial 
injuries, obscuring the effectiveness of NSE a diagnostic biomarker for TBI alone.   
 Strengths of this systematic review include the use of procedures developed 
specifically with such studies in mind, the assessment of the quality of the chosen 
citations by closely examining risk of bias, and the use of an established search strategy 
that utilized multiple databases without any restrictions on language. This allowed our 
results to be both comprehensive and exhaustive. The methods described here were based 
on the current standard for conducting and recording the results of meta analyses and 
systematic reviews.  
 Correlating data and outcomes between animal and human studies is often fraught 
with translational barriers, one of which is a lack of homogeneity of reported data in 
preclinical studies. Studies that use different injury models to induce TBI may correlate 
with different outcomes. For example, not every study using a blast model accounts for 
abdominal damage and the elevated NSE levels that are associated with it. The definition 
of “mild,” “moderate,” and “severe” TBI in preclinical trials are also a topic of 
controversy. There is very little agreement between what constitutes a mild injury versus 
a moderate one. This issue is further confounded with the use of multiple models, 
bringing up the question of how one determines an equivalent injury between a blast 
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model and a weight drop model. These discrepancies need to be addressed further to 
increase the effectiveness of data translation between the preclinical and clinical realms. 
Conclusion 
 Although previous systematic reviews have described the benefits of utilizing 
NSE as a biomarker for TBI in humans, there is a dearth of systematic reviews and meta-
analyses exploring the relationship between NSE levels and TBI in animals. The 
development of animal models is paramount to our understanding of several human 
pathologies. The number of preclinical studies performed every year continues to rise, but 
the number of new interventions making it to a clinical setting to address these issues 
continues to fall.29 It is clear from the results of this study that despite a large amount of 
available data detailing animal models in TBI, few data are reported in a consistent 
enough fashion to be utilized effectively by reviewers. Systematic reviews can help to 
confront some of the issues in translational TBI research by providing a holistic 
viewpoint on a topic that allows researchers to examine the current landscape of available 
literature while remaining transparent about risk of bias. Therefore, more structured 
methods should be considered to bridge the gap not only between preclinical and clinical 
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